Our Pricing

Switching From Mounjaro to Wegovy: Complete UK Clinical Guide

Published on: June 03, 2026

Switching from Mounjaro to Wegovy is a transition that many UK patients consider when optimising their weight loss treatment plan. Both medications are highly effective GLP-1 receptor agonists, but they contain different active ingredients—tirzepatide in Mounjaro and semaglutide in Wegovy—which means the switch requires careful clinical planning. This guide provides evidence-based protocols for transitioning safely between these treatments under UK prescriber supervision.

Why Consider Switching From Mounjaro to Wegovy?

Patients consider switching from Mounjaro to Wegovy for several clinical and practical reasons. Cost is a significant factor—Wegovy is priced from £124.99 at Cured Pharmacy, making it more accessible than Mounjaro at £124.99 for many patients seeking long-term weight management [1]. Additionally, some individuals experience better tolerability with semaglutide compared to tirzepatide, particularly regarding gastrointestinal side effects.

Clinical response also guides switching decisions. While Mounjaro demonstrated superior average weight loss in head-to-head trials, some patients achieve their target weight with Wegovy and prefer to maintain results on a single-agonist GLP-1 medication [2]. Supply considerations occasionally necessitate transitions, as UK availability can fluctuate for both treatments. Any switch must be supervised by a UK-registered prescriber who can assess your individual response and medical history.

Clinical Protocol for Switching From Mounjaro to Wegovy

The recommended protocol when switching from Mounjaro to Wegovy depends on your current tirzepatide dose and treatment duration. UK prescribers typically advise a washout period of 4-7 days between your last Mounjaro injection and your first Wegovy dose, allowing tirzepatide levels to decline sufficiently [3]. This timing minimises overlapping GLP-1 receptor stimulation and reduces the risk of enhanced gastrointestinal side effects.

Dose mapping is not direct between these medications. If you are on Mounjaro 5mg, your prescriber will likely start you on Wegovy 0.25mg for the first month, following the standard Wegovy titration schedule. Patients on higher Mounjaro doses (10mg or 15mg) may begin Wegovy at 0.5mg after completing the 0.25mg starter dose, but this requires individual clinical assessment [4]. The goal is to minimise side effects while maintaining therapeutic efficacy during the transition.

Recommended Dose Transition Schedule

A typical switching from Mounjaro to Wegovy schedule begins with a 4-7 day gap after your final Mounjaro injection. Start Wegovy at 0.25mg weekly for 4 weeks, then escalate to 0.5mg weekly for 4 weeks, followed by 1mg weekly. Continue monthly increases to 1.7mg and finally 2.4mg as tolerated [3]. This gradual titration reduces nausea and other common side effects. Your UK prescriber will adjust this schedule based on your tolerance and weight loss progress, ensuring the transition supports your clinical goals without compromising safety.

Expected Outcomes When Switching From Mounjaro to Wegovy

Patients switching from Mounjaro to Wegovy should anticipate continued weight loss or maintenance, though the rate may differ. In the STEP 1 trial, Wegovy participants achieved an average of 14.9% total body weight loss over 68 weeks [5]. Mounjaro's SURMOUNT-1 trial showed higher average losses of 20.9% at the 15mg dose [2]. However, individual responses vary significantly, and many patients maintain their weight successfully on Wegovy after initial loss with Mounjaro.

The transition period—typically the first 8-12 weeks—may involve temporary fluctuations in appetite suppression and weight trajectory. Some patients report slightly increased hunger during the initial Wegovy titration compared to their stable Mounjaro dose, which normalises as semaglutide reaches therapeutic levels. Monitoring your weight weekly and maintaining consistent dietary habits helps your prescriber optimise your Wegovy dose during this adjustment phase.

Side Effects and Tolerability When Switching From Mounjaro to Wegovy

The side effect profile when switching from Mounjaro to Wegovy is generally manageable, though some patients experience renewed gastrointestinal symptoms during the transition. Nausea, diarrhoea, and constipation are the most common effects reported with both medications [1][5]. Because Wegovy uses a different GLP-1 mechanism (single receptor agonist versus Mounjaro's dual GIP/GLP-1 action), your body requires time to adjust even if you tolerated tirzepatide well.

Starting Wegovy at the lowest dose (0.25mg) and following the prescribed titration schedule significantly reduces side effect severity. Patients who experienced minimal issues on Mounjaro often find Wegovy equally tolerable, while those who struggled with tirzepatide's gastrointestinal effects sometimes report improved comfort with semaglutide. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods during the first month supports better tolerability. Any persistent or severe symptoms should be reported to your UK prescriber immediately for dose adjustment or clinical review.

Managing Nausea During the Transition

Nausea is the most frequently reported side effect when switching from Mounjaro to Wegovy, affecting approximately 20-30% of patients during initial titration [5]. To minimise discomfort, take your Wegovy injection on the same day each week, preferably in the evening after a light meal. Ginger tea, small frequent meals, and avoiding strong odours can provide symptomatic relief. If nausea persists beyond the first two weeks at a new dose, contact your prescriber—they may recommend extending the current dose for an additional month before escalating, ensuring your body fully adapts to semaglutide.

Cost Comparison: Switching From Mounjaro to Wegovy in the UK

Financial considerations often drive the decision when switching from Mounjaro to Wegovy. At Cured Pharmacy, Wegovy is available from £124.99 compared to Mounjaro at £124.99, representing a significant monthly saving for patients requiring long-term treatment [1]. Over a 12-month weight management programme, this difference can exceed £124.99 making Wegovy a more sustainable option for many UK patients who have achieved their initial weight loss goals.

Both medications require ongoing prescription and clinical monitoring, with costs remaining consistent throughout treatment. Cured Pharmacy offers transparent upfront pricing and a £20 discount on your first order with code Weightlossnew, reducing the initial Wegovy cost to £124.99. All prescriptions are subject to clinical assessment by UK-registered prescribers, ensuring your switch is medically appropriate. The cost savings of Wegovy do not compromise efficacy—semaglutide remains one of the most effective weight loss medications available, with robust clinical trial data supporting long-term use [5].

How to Switch From Mounjaro to Wegovy at Cured Pharmacy

Switching from Mounjaro to Wegovy through Cured Pharmacy is straightforward and clinically supervised. Begin by completing the online consultation, which takes under 3 minutes and is reviewed by a UK-registered prescriber from our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). During the assessment, indicate your current Mounjaro dose, treatment duration, and reason for switching—this information helps the prescriber determine the appropriate starting dose and titration schedule for Wegovy.

Once approved, your Wegovy prescription is dispensed from our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging with next-day delivery options available. You will receive the complete Wegovy starter pack including all necessary doses for the initial titration phase. Ongoing prescriptions are managed through follow-up consultations, ensuring continuous clinical oversight as you progress through the dose escalation. Our team is available at (+44) 116 4646009 for any questions during your transition, providing the expert support you need when switching from Mounjaro to Wegovy safely and effectively.

Documentation Required for Your Switch

When switching from Mounjaro to Wegovy, your UK prescriber will need specific information to ensure safe transition. Prepare details of your current Mounjaro dose, duration of treatment, total weight lost, any side effects experienced, and your target weight goal. If you have recent blood test results (HbA1c, liver function, or lipid panel), these can inform your prescriber's decision, though they are not mandatory for weight loss prescriptions. Accurate medical history disclosure—including any cardiovascular conditions, thyroid disorders, or pancreatitis history—is essential for clinical safety and treatment optimisation.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
3. Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., ... & Schwartz, S. L. (2018). Switching between GLP-1 receptor agonists: Rationale and practical guidance. Diabetes Therapy, 9(6), 2175-2184. [accessed 13 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Sjöström, C. D. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.